Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Reneuron Share Price
  4. Reneuron Share Regulatory News
  5. Price Monitoring Extension

Pin to quick picksReneuron Regulatory News (RENE)

Reneuron Information
  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Price Monitoring Extension

26 Apr 2019 16:35

RNS Number : 3033X
ReNeuron Group plc
26 April 2019
 

Price Monitoring Extension

The auction call period has been extended in this security by 5 minutes.

Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PMELLFVESEIRFIA
6789101112131415
Date   Source Headline
12th Jul 20107:00 amRNSResult of pre-clinical studies
29th Jun 20107:00 amRNSPreliminary Results
17th Jun 20107:00 amRNSPreliminary Results Notification
13th May 20102:38 pmRNSBlock listing application
29th Apr 20107:00 amRNSNew positive data to be presented at US conference
1st Apr 20109:58 amRNSHolding in Company
31st Mar 20104:35 pmRNSHolding(s) in Company
22nd Mar 201010:44 amRNSReNeuron cited as UK regenerative medicine leader
18th Mar 20107:00 amRNSReNeuron signs further manufacturing contracts
15th Mar 20102:44 pmRNSSecond Closing of the Placing
12th Mar 201012:18 pmRNSResult of General Meeting
3rd Mar 20107:00 amRNSReNeuron presents pre-clinical efficacy data
22nd Feb 20107:00 amRNSReNeuron Announces Fundraising
18th Feb 20107:00 amRNSRetinal Stem Cell Research Grant
10th Feb 20107:00 amRNSFinal Approval Received To Commence Stroke Trial
8th Feb 201012:55 pmRNSIssue of Ordinary Shares
1st Feb 20107:00 amRNSClinical Advisory Board appointments
28th Jan 20107:00 amRNSRegulatory update
27th Jan 201011:42 amRNSReNeuron welcomes "Life Sciences 2010" report
1st Dec 20097:00 amRNSIssue of Ordinary Shares
27th Nov 20097:00 amRNSTwo grants awarded by regenerative funding program
26th Nov 20097:02 amRNS?5 million equity funding facility secured
26th Nov 20097:00 amRNSHalf Yearly Report
23rd Nov 20097:00 amRNSNotice of Results
16th Nov 20097:00 amRNSPositive data presented at leading US conference
22nd Oct 20091:49 pmRNSReNeuron to present at Royal Society of Medicine
2nd Oct 20097:00 amRNSPublication of new research using ReNcell
17th Sep 200910:47 amRNSResult of AGM
17th Sep 20097:00 amRNSAGM Statement
14th Sep 20097:02 amRNSTrading Platform
14th Sep 20097:00 amRNSChange of Adviser
10th Sep 20097:00 amRNSAngel and Reneuron announce contract
10th Sep 20097:00 amRNSRe Agreement
9th Sep 20095:00 pmRNSHolding(s) in Company
12th Aug 20097:00 amRNSDirector/PDMR Shareholding
11th Aug 20097:00 amRNSPublication of papers in peer-reviewed journals
10th Aug 20099:28 amRNSPublication of pre-clinical data
31st Jul 200911:21 amRNS2008/09 Annual Report and Accounts
30th Jul 200910:05 amRNSRegulatory Update
14th Jul 20093:48 pmRNSLaunch of "Life Sciences Blueprint"
8th Jul 20099:33 amRNSPublication of data on lead CTX stem cell line
30th Jun 20097:00 amRNSFinal Results
29th Jun 20093:44 pmRNSHolding(s) in Company
24th Jun 200910:30 amRNSHolding(s) in Company
19th Jun 200912:17 pmRNSNotice of Results
12th Jun 20092:56 pmRNSHolding(s) in Company
9th Jun 20097:00 amRNSStem cells manufacturing contract signed
21st May 20098:43 amRNSHolding(s) in Company
19th May 20091:21 pmRNSHolding(s) in Company
19th May 20091:18 pmRNSHolding(s) in Company
6789101112131415

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.